Byrne, R. A. et al. 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG. Eur. Heart J. 44, 4310–4320 (2023).

Article  PubMed  Google Scholar 

Lawton, J. S. et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145, e18–e114 (2022).

PubMed  Google Scholar 

Neumann, F. J. et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur. Heart J. 40, 87–165 (2019).

Article  PubMed  Google Scholar 

Kithcart, A. P. & Beckman, J. A. ACC/AHA versus ESC guidelines for diagnosis and management of peripheral artery disease: JACC guideline comparison. J. Am. Coll. Cardiol. 72, 2789–2801 (2018).

Article  PubMed  Google Scholar 

Aboyans, V. et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Eur. Heart J. 39, 763–816 (2018).

Article  PubMed  Google Scholar 

Gerhard-Herman, M. D. et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 69, 1465–1508 (2017).

Article  PubMed  Google Scholar 

Thuijs, D. et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet 394, 1325–1334 (2019).

Article  PubMed  Google Scholar 

Fearon, W. F. et al. Fractional flow reserve-guided PCI as compared with coronary bypass surgery. N. Engl. J. Med. 386, 128–137 (2022).

Article  PubMed  Google Scholar 

Farber, A. et al. Surgery or endovascular therapy for chronic limb-threatening ischemia. N. Engl. J. Med. 387, 2305–2316 (2022).

Article  PubMed  Google Scholar 

Caliskan, E. et al. Saphenous vein grafts in contemporary coronary artery bypass graft surgery. Nat. Rev. Cardiol. 17, 155–169 (2020).

Article  PubMed  Google Scholar 

Hess, C. N. et al. Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV. Circulation 130, 1445–1451 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Conte, M. S. et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J. Vasc. Surg. 43, 742–751 (2006).

Article  PubMed  Google Scholar 

Goldman, S. et al. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study. J. Am. Coll. Cardiol. 44, 2149–2156 (2004).

Article  PubMed  Google Scholar 

Gaudino, M. et al. Graft failure after coronary artery bypass grafting and its association with patient characteristics and clinical events: a pooled individual patient data analysis of clinical trials with imaging follow-up. Circulation 148, 1305–1315 (2023).

Article  PubMed  Google Scholar 

Sandner, S. et al. Association of dual antiplatelet therapy with ticagrelor with vein graft failure after coronary artery bypass graft surgery: a systematic review and meta-analysis. JAMA 328, 554–562 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Valgimigli, M. et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ 373, n1332 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Zhao, Q. et al. Effect of ticagrelor plus aspirin, ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary artery bypass grafting: a randomized clinical trial. JAMA 319, 1677–1686 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Kulik, A., Abreu, A. M., Boronat, V. & Ruel, M. Intensive versus moderate statin therapy and early graft occlusion after coronary bypass surgery: the aggressive cholesterol therapy to inhibit vein graft events randomized clinical trial. J. Thorac. Cardiovasc. Surg. 157, 151–161.e1 (2019).

Article  PubMed  Google Scholar 

Goodman, S. G. et al. Effects of alirocumab on cardiovascular events after coronary bypass surgery. J. Am. Coll. Cardiol. 74, 1177–1186 (2019).

Article  PubMed  Google Scholar 

Eisen, A. et al. The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. Eur. Heart J. 37, 3576–3584 (2016).

Article  PubMed  Google Scholar 

Alexander, J. H. et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 294, 2446–2454 (2005).

Article  PubMed  Google Scholar 

Goldstein, D. J. et al. External support for saphenous vein grafts in coronary artery bypass surgery: a randomized clinical trial. JAMA Cardiol. 7, 808–816 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Hajipour, M. J. et al. Nanoscale technologies for prevention and treatment of heart failure: challenges and opportunities. Chem. Rev. 119, 11352–11390 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Mahmoudi, M. et al. Multiscale technologies for treatment of ischemic cardiomyopathy. Nat. Nanotechnol. 12, 845–855 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Chen, W. et al. Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis. Nat. Rev. Cardiol. 19, 228–249 (2022).

Article  PubMed  Google Scholar 

Lobatto, M. E., Fuster, V., Fayad, Z. A. & Mulder, W. J. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat. Rev. Drug Discov. 10, 835–852 (2011).

Article  PubMed  PubMed Central  Google Scholar 

Smith, B. R. & Edelman, E. R. Nanomedicines for cardiovascular disease. Nat. Cardiovasc. Res. 2, 351–367 (2023).

Article  PubMed  Google Scholar 

Huang, X. et al. Synthesis of siRNA nanoparticles to silence plaque-destabilizing gene in atherosclerotic lesional macrophages. Nat. Protoc. 17, 748–780 (2022).

Article  PubMed  PubMed Central  Google Scholar 

He, Z. et al. Resolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment. Nat. Nanotechnol. 19, 1386–1398 (2024).

Article  PubMed  Google Scholar 

Tierney, J. W. et al. Therapeutic MK2 inhibition blocks pathological vascular smooth muscle cell phenotype switch. JCI Insight 6, e142339 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Evans, B. C. et al. MK2 inhibitory peptide delivered in nanopolyplexes prevents vascular graft intimal hyperplasia. Sci. Transl. Med. 7, 291ra295 (2015).

Article  Google Scholar 

Decano, J. L. et al. Systems approach to discovery of therapeutic targets for vein graft disease: PPARα pivotally regulates metabolism, activation, and heterogeneity of macrophages and lesion development. Circulation 143, 2454–2470 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Nishio, H. et al. MicroRNA-145-loaded poly(lactic-co-glycolic acid) nanoparticles attenuate venous intimal hyperplasia in a rabbit model. J. Thorac. Cardiovasc. Surg. 157, 2242–2251 (2019).

Article  PubMed  Google Scholar 

Rajathurai, T. et al. Periadventitial rapamycin-eluting microbeads promote vein graft disease in long-term pig vein-into-artery interposition grafts. Circ. Cardiovasc. Interv. 3, 157–165 (2010).

Article  PubMed